Janus kinase 2-signal transducer and activator of transcription pathway (JAK2-STAT pathway)

The "Janus kinase 2-signal transducer and activator of transcription pathway" refers not to a single molecular target but rather a cellular signal transduction cascade involving Janus kinases—especially JAK2, a non-receptor tyrosine kinase—and signal transducers and activators of transcription (STAT) proteins. This JAK/STAT signaling axis is activated when extracellular ligands such as cytokines bind their cell surface receptors; these receptors then activate associated JAK kinases like JAK2, which phosphorylate both themselves and the receptor. This creates docking sites for cytoplasmic STAT proteins that are subsequently phosphorylated by activated JAKs. Phosphorylated STATs dimerize and move into the nucleus where they regulate gene expression involved in processes such as cell growth, differentiation, apoptosis inhibition/promotion, immune function modulation, inflammation control, hematopoiesis regulation—and when dysregulated—can contribute to cancer development or immune disorders. Because "Janus kinase 2-signal transducer and activator of transcription pathway" describes an entire biological process rather than a discrete protein/receptor/enzyme entity typically considered a drug target ("target"), it is not itself directly druggable; instead individual components such as JAK2 or specific STAT family members serve as therapeutic targets. Thus this entry should be flagged as incorrect if your intent is to capture only canonical molecular targets suitable for structured databases. If you need information on specific molecular targets within this system—such as "Janus kinase 2" (JAK2) alone or particular "Signal Transducer And Activator Of Transcription" family members—please specify so structured data can be provided at that level.

Other names

JAK/STAT signaling pathwayJanus kinase/signal transducers and activators of transcription pathwayJAK2-STAT signaling axis

Drugs targeting this pathway may act by inhibiting the activity of Janus kinases (e.g., small molecule inhibitors), modulating cytokine receptor activation, or interfering with STAT phosphorylation/translocation. Some drugs are monoclonal antibodies that block upstream cytokines or their receptors, thereby preventing downstream activation of the JAK/STAT cascade.